Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Prevalence of self-medication practice with herbal products among non-psychotic psychiatric patients from southeastern Serbia: A cross-sectional study.

Stojanović NM, Samardžić L, Randjelović PJ, Radulović NS.

Saudi Pharm J. 2017 Sep;25(6):884-890. doi: 10.1016/j.jsps.2017.02.002. Epub 2017 Feb 10.

2.

Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.

Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R.

BMJ. 2017 Feb 21;356:j603. doi: 10.1136/bmj.j603.

3.

Ophiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse model.

Huang CW, Hong TW, Wang YJ, Chen KC, Pei JC, Chuang TY, Lai WS, Tsai SH, Chu R, Chen WC, Sheen LY, Takahashi S, Ding ST, Shen TL.

BMC Complement Altern Med. 2016 Aug 24;16(1):310. doi: 10.1186/s12906-016-1278-7.

4.

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.

Gommoll CP, Greenberg WM, Chen C.

J Drug Assess. 2014 Jan 16;3(1):10-9. doi: 10.3109/21556660.2014.884505. eCollection 2014.

5.

Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.

Oosting RS, Chan JS, Olivier B, Banerjee P, Choi YK, Tarazi F.

Psychopharmacology (Berl). 2016 Mar;233(6):1025-34. doi: 10.1007/s00213-015-4198-1. Epub 2016 Jan 13.

6.

Competing priorities in treatment decision-making: a US national survey of individuals with depression and clinicians who treat depression.

Barr PJ, Forcino RC, Mishra M, Blitzer R, Elwyn G.

BMJ Open. 2016 Jan 8;6(1):e009585. doi: 10.1136/bmjopen-2015-009585.

7.

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.

Gommoll C, Forero G, Mathews M, Nunez R, Tang X, Durgam S, Sambunaris A.

Int Clin Psychopharmacol. 2015 Nov;30(6):297-306. doi: 10.1097/YIC.0000000000000096.

8.

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.

Clayton AH, Gommoll C, Chen D, Nunez R, Mathews M.

Int Clin Psychopharmacol. 2015 Jul;30(4):216-23. doi: 10.1097/YIC.0000000000000075.

9.

A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.

Gommoll C, Durgam S, Mathews M, Forero G, Nunez R, Tang X, Thase ME.

Depress Anxiety. 2015 Jun;32(6):451-9. doi: 10.1002/da.22365. Epub 2015 Apr 17.

10.

Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial.

Farnia V, Shirzadifar M, Shakeri J, Rezaei M, Bajoghli H, Holsboer-Trachsler E, Brand S.

Neuropsychiatr Dis Treat. 2015 Mar 9;11:625-35. doi: 10.2147/NDT.S78696. eCollection 2015.

11.

Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study.

Johnson CF, Dougall NJ, Williams B, MacGillivray SA, Buchanan AI, Hassett RD.

BMC Fam Pract. 2014 Dec 24;15:210. doi: 10.1186/s12875-014-0210-9.

12.

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Mathews M, Gommoll C, Chen D, Nunez R, Khan A.

Int Clin Psychopharmacol. 2015 Mar;30(2):67-74. doi: 10.1097/YIC.0000000000000057.

13.

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.

Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA.

Transl Psychiatry. 2014 Oct 14;4:e469. doi: 10.1038/tp.2014.105.

14.

Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.

Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF 3rd.

J Clin Psychiatry. 2014 Aug;75(8):e785-93. doi: 10.4088/JCP.13m08725.

15.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.

BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

16.

Identifying Chinese herbal medicine for premenstrual syndrome: implications from a nationwide database.

Chen HY, Huang BS, Lin YH, Su IH, Yang SH, Chen JL, Huang JW, Chen YC.

BMC Complement Altern Med. 2014 Jun 27;14:206. doi: 10.1186/1472-6882-14-206.

18.

Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.

Crawford AA, Lewis S, Nutt D, Peters TJ, Cowen P, O'Donovan MC, Wiles N, Lewis G.

Psychopharmacology (Berl). 2014 Aug;231(15):2921-31. doi: 10.1007/s00213-014-3467-8. Epub 2014 Feb 13.

19.

Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder.

Safa M, Sadr S, Talischi F, Ghasem Boroujerdi F.

Ther Adv Psychopharmacol. 2013 Dec;3(6):306-13. doi: 10.1177/2045125313488906.

20.

Management strategies for SSRI-induced sexual dysfunction.

Rizvi SJ, Kennedy SH.

J Psychiatry Neurosci. 2013 Sep;38(5):E27-8. doi: 10.1503/jpn.130076. No abstract available.

Supplemental Content

Support Center